Meeting News CoverageVideo

VIDEO: Speaker compares available therapies for BRAF–positive melanoma

NEW YORK — Michael B. Atkins, MD, deputy director of the Georgetown Lombardi Comprehensive Cancer Center, discussed how clinicians can decide whether to use immunotherapy or molecularly targeted therapy to treat patients with BRAF–positive melanoma at HemOnc Today Melanoma and Cutaneous Malignancies.

Atkins presented background on treatment with ipilimumab (Yervoy, Bristol Myers Squibb), nivolumab (Opdivo, Bristol Myers Squibb), BRAF inhibitors and combinations of these agents.

“Hopefully the research that we’re doing ... in how to treat patients who don’t respond or become resistant to these various therapies will bring us to where we want to be, which is now, I think, within sight,” he said.

NEW YORK — Michael B. Atkins, MD, deputy director of the Georgetown Lombardi Comprehensive Cancer Center, discussed how clinicians can decide whether to use immunotherapy or molecularly targeted therapy to treat patients with BRAF–positive melanoma at HemOnc Today Melanoma and Cutaneous Malignancies.

Atkins presented background on treatment with ipilimumab (Yervoy, Bristol Myers Squibb), nivolumab (Opdivo, Bristol Myers Squibb), BRAF inhibitors and combinations of these agents.

“Hopefully the research that we’re doing ... in how to treat patients who don’t respond or become resistant to these various therapies will bring us to where we want to be, which is now, I think, within sight,” he said.

    See more from HemOnc Today New York